NCT06435429Phase 3Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04-28Estimated
Enrollment · participants550Estimated
Source updated2026-02-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 26 Sep 2028. After: 28 Apr 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview